Skip to main content
. 2021 Mar 18;22(6):3095. doi: 10.3390/ijms22063095

Figure 2.

Figure 2

Effect of glucocorticoid receptor (GR) antagonist mifepristone on sleep disturbances in both male and female Wistar and msP rats. Mifepristone (60 mg/kg) was injected intraperitoneally, and rats were subjected to the comprehensive lab animal monitoring system (CLAMS) test after 90 min. Mifepristone had no effect on ameliorating sleep disturbances. (A) average bout duration, (B) total sleep time, (C) number of sleep bouts in vehicle (n = 8) or mifepristone-treated (n = 8) male Wistar rats and vehicle (n = 7) or mifepristone-treated (n = 8) male msP rats. (D) average bout duration, (E) total sleep time, (F) number of sleep bouts in vehicle (n = 8) or mifepristone-treated (n = 8) female Wistar rats and vehicle (n = 8) or mifepristone-treated (n = 8) female msP rats. (G) average bout duration, (H) total sleep time, (I) number of sleep bouts in male Wistar (n = 8) and male msP (n = 7) rats, female Wistar (n = 8) and female msP (n = 8) rats. Results are expressed as mean ± SEM. Two-way ANOVA followed by Fisher’s LSD protected post hoc tests when the interaction between variables occurred. Main effect of genotype, * p ≤ 0.05. Post hoc test revealed significant differences between treatments, # p ≤ 0.05.